
Loading, please wait...

Loading, please wait...

Rapidly identifying patients at low risk for acute coronary syndrome (ACS) is a critical challenge in emergency medicine. Furthermore, clinical decision-making relies heavily on validated risk scores alongside high-sensitivity troponin testing. Recent research has highlighted the modified HEART score as a superior tool for this purpose. This simplified scoring system aims to facilitate safer and more efficient discharge of patients presenting with non-traumatic chest pain.
A prospective observational study conducted at the University Hospital of Bologna evaluated the modified HEART score against the classic HEART and GRACE scores. The study enrolled adult patients admitted with chest pain and followed them for 90 days to monitor for major adverse cardiovascular events (MACE) and mortality. Notably, the mHEART score demonstrated a higher area under the curve (AUC) of 0.891, compared to 0.884 for the classic HEART score and 0.804 for the GRACE score. These results indicate that the modified version offers enhanced diagnostic performance in an acute setting.
One of the most significant advantages of using the modified HEART score is its ability to categorize a larger volume of patients as low-risk without compromising safety. Specifically, the mHEART score classified 47.9% of patients as low-risk, whereas the classic HEART score identified only 36.3%. In addition, the cumulative incidence of MACE in the mHEART low-risk group was only 1.0%, with a negative predictive value (NPV) of 99.0%. Consequently, healthcare providers can confidently discharge nearly half of their chest pain patients early, significantly reducing emergency department overcrowding. Therefore, implementing this modified score could streamline clinical workflows and improve resource allocation.
The modified HEART score (mHEART) is a simplified version of the original HEART score designed to improve the identification of low-risk patients with chest pain in the emergency department.
Research indicates that the mHEART score has a significantly higher diagnostic accuracy (AUC 0.891) than the GRACE score (AUC 0.804) for predicting 90-day major adverse cardiovascular events.
Yes, the mHEART score demonstrated a negative predictive value (NPV) of 99.0%, making it a highly reliable tool for identifying patients who can be safely discharged from the emergency department.
Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or a professional recommendation. Refer to the latest local and national guidelines for clinical practice.
References

Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.


New research shows the modified HEART score (mHEART) identifies low-risk ACS patients more accurately than classic HEART or GRACE scores in the ED....
4 months ago

Review how tailored exercise programs benefit frail older patients with heart failure. Explore pathophysiological mechanisms, individualized training prescriptions, and strategies to overcome adherence barriers in clinical practice.
Today

Leucine Rich Bio has introduced South Asia's first comprehensive vaginal microbiome test, BugSpeaks. By profiling microbial dysbiosis, pathogens, and antimicrobial resistance, this next-generation diagnostic platform provides clinicians with deeper insights into recurrent infections, fertility, and reproductive health.
Today

In high-risk pulmonary embolism complicated by severe anemia and active uterine bleeding, systemic thrombolysis is contraindicated. Large-bore aspiration thrombectomy provides rapid hemodynamic rescue without fibrinolysis, supported by inferior vena cava filter placement and multidisciplinary critical care.
Today

This comparative study evaluates posterior labral tears with and without glenohumeral instability, highlighting distinct demographic patterns, MRI underestimation in stable shoulders, and successful arthroscopic repair outcomes.
Today

A clinical study demonstrates that early intervention with tocilizumab, either as monotherapy or bridged with corticosteroids, achieves significant proptosis reduction and resolves active inflammation in treatment-naive thyroid eye disease.
Today